news
UK approval for Pompe Disease therapy
16 August 2023 | By
The MHRA has granted marketing authorisation for a two-component therapy for adults with late-onset Pompe Disease, a rare disorder.
List view / Grid view
Amicus Therapeutics
news
Amicus submits EU marketing authorisation application for Fabry monotherapy Galafold
3 June 2015 | By Victoria White
Amicus Therapeutics has submitted a MAA to request full approval in the EU of Galafold for Fabry patients who have amenable genetic mutations...
news
Top-line six-month primary treatment period results from first Phase III Fabry monotherapy study
19 December 2012 | By GlaxoSmithKline
Six-month primary treatment period results...
news
GlaxoSmithKline and Amicus Therapeutics expand Fabry disease collaboration
17 July 2012 | By GlaxoSmithKline
Fabry products to be commercialised by Amicus in US and by GSK ex-US...
news
GlaxoSmithKline and Amicus Therapeutics commence second phase III study of Amigal™ for Fabry disease
12 September 2011 | By GSK
The first patient has commenced dosing in a Phase III global registration study...
